Table 2

Association between BMI category and the probability of achieving sustained MDA among patients by discrete time proportional odds analysis

Univariate modelMultivariate—reduced model
OR95% CIp ValueOR95% CIp Value
Gender: female0.700.56 to 0.880.0020.710.56 to 0.890.003
Age*0.840.77 to 0.920.00020.870.79 to 0.950.003
Duration of PsA*0.840.75 to 0.920.00050.880.78 to 0.990.03
BMI category†
Overweight versus normal0.650.50 to 0.850.0020.660.50 to 0.870.003
Obesity versus normal0.520.40 to 0.67<0.00010.530.41 to 0.69<0.0001
DMARDs use0.740.59 to 0.930.0090.770.61 to 0.970.03
TNFα blockers1.070.85 to 1.350.54
NSAIDs0.590.47 to 0.74<0.00010.550.43 to 0.70<0.0001
  • *10-year increase.

  • †Overweight (BMI 25–30), obesity (BMI > 30).

  • BMI, body mass index; DMARDs, disease modifying anti-rheumatic drugs; MDA, minimal disease activity; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis.